TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24446523
Drug: Dolutegravir (DTG)
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dolutegravir (DTG) 50 mg BID
Study: 22260745
Drug: 26% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 26% NaCl and heparin
Study: 10084064
Drug: Standard heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard heparin
Study: 11076326
Drug: Thyroxine (T4)
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thyroxine (T4) supplementation (10 or 20 micrograms/kg; intravenous or nasogastric tube) for 21 days
Study: 1574972
Drug: Crystalloid volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid volume loading (10 ml.kg‐1 b.w.)
Study: 2859650
Drug: Somatostatin-28 (SS-28)
Normalized name: Somatostatine
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin-28 (SS-28) infusion
Study: 2859650
Drug: Somatostatin-14 (SS-14)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin-14 (SS-14) infusion at 75 pmol/kg-h
Study: 17873677
Drug: 108 mg
Normalized name: camphor 108 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 108 mg extended-release methylphenidate (osmotic release oral system [OROS])
Study: 15857282
Drug: N-chlorotaurine (1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-chlorotaurine (1% aqueous solution)
Study: 9382121
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg alendronate
Study: 6232583
Drug: Hydrochlorothiazide 50
Normalized name: hydrochlorothiazide 50 MG
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide 50 mg/day (group II, n = 19)
Study: 25215557
Drug: Calcium (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium (1000 mg/d)
Study: 25215557
Drug: Joint calcium
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Joint calcium (1000 mg/d) and vitamin D (50000 IU/wk)
Study: 1461853
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of intravenous Augmentin (amoxycillin 250 mg and clavulanic acid 125 mg)
Study: 1461853
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of intravenous Augmentin (amoxycillin 250 mg and clavulanic acid 125 mg) every 8 hours
Study: 1461853
Drug: One dose
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One dose of intravenous Augmentin
Study: 1461853
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses of intravenous Augmentin
Study: 19404632
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination (200 mg artesunate + 540 mg amodiaquine)
Study: 19404632
Drug: Loose combination
Normalized name: loose wheat smut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loose combination (200 mg artesunate + 612 mg amodiaquine)
Study: 16188428
Drug: Dexamethasone 4
Normalized name: dexamethasone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 4 mg (group A)
Study: 16188428
Drug: Dexamethasone 10
Normalized name: dexamethasone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 10 mg (group B)
Study: 16188428
Drug: Dexamethasone 10
Normalized name: dexamethasone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 10 mg as sub‐mucosal injection (group C)
Study: 3838425
Drug: Orange juice
Normalized name: Orange juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orange juice (13 g of carbohydrate)
Study: 3838425
Drug: Whole milk
Normalized name: Calcium fortified whole milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole milk (13 g of carbohydrate)
Study: 3838425
Drug: Skim milk
Normalized name: skim milk
DrugBank: Skim milk (DB15546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Skim milk (13 g of carbohydrate)
Study: 25335963
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy (CBT) plus treatment as usual
Study: 26491889
Drug: Ialuril Soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ialuril Soft Gels in hypo-extreme group
Study: 22752862
Drug: Fidaxomicin 200
Normalized name: fidaxomicin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fidaxomicin 200 mg twice per day for 10 days
Study: 22752862
Drug: Vancomycin 125
Normalized name: vancomycin 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 125 mg 4 times per day for 10 days
Study: 9580856
Drug: Iodine-123 administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodine-123 administration only (G0)
Study: 12517685
Drug: Caffeine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (250 mg)
Study: 25960375
Drug: PCI +
Normalized name: PCI-27483
DrugBank: PCI-27483 (DB13000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCI + Optimal Medical Therapy (OMT)
Study: 24094693
Drug: Medium-titration group
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium-titration group (150mg/day every 4 days)
Study: 19001472
Drug: Culotte stenting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culotte stenting with drug-eluting stents
Study: 12622302
Drug: Routine GP
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine GP treatment
Study: 10861652
Drug: Lamivudine treatment
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine treatment continued for 2 years
Study: 9144683
Drug: paclitaxel/cisplatin/G-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: paclitaxel/cisplatin/G-CSF
Study: 3131406
Drug: topical nasal
Normalized name: Nasal Inhalant
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical nasal treatment
Study: 24949547
Drug: Iron supplement
Normalized name: Iron supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplement group (SG)
Study: 22610268
Drug: Midodrine 10-30
Normalized name: midodrine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midodrine 10-30 mg/day
Study: 327987
Drug: Baclofen (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (70 to 80 mg daily maximum, titrated)
Study: 31793473
Drug: Universal adhesive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal adhesive application with no treatment (control)
Study: 19453031
Drug: On-demand therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand therapy with omeprazole 20 mg (Group A1)
Study: 15060418
Drug: 20 microg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 microg/min t‐PA infusion
Study: 15060418
Drug: 40 microg/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 microg/min t‐PA infusion
Study: 2194715
Drug: terbinafine (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: terbinafine (125 mg b.i.d.)
Study: 2194715
Drug: griseofulvin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: griseofulvin (500 mg b.i.d.)
Study: 353623
Drug: Calcium dobesilate
Normalized name: CALCIUM DOBESILATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium dobesilate (750 mg per day)
Study: 353623
Drug: Calcium dobesilate
Normalized name: CALCIUM DOBESILATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium dobesilate (1,000 mg per day)
Study: 28040660
Drug: Standard chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemoradiotherapy (SFX) with cisplatin (100 mg/m2 IV × 3)
Study: 26237830
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment with oral sanhuangwuji powder, ginger-partitioned acupoint stimulation at zusanli (ST 36), and ARDs
Study: 23774436
Drug: Gatifloxacin 400
Normalized name: gatifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gatifloxacin 400 mg daily doses
Study: 16942472
Drug: Osteopathic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic treatment plus progressive muscular relaxation (PMR) exercises
Study: 14964492
Drug: Flap surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flap surgery and laser treatment using an energy level of 0.8 W
Study: 12237921
Drug: Irinotecan (CPT-11)
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan (CPT-11) 100 mg/m² over 90 minutes, Paclitaxel 175 mg/m² over 3 hours, Carboplatin AUC 5 over 30 minutes, administered on the first day of each 21-day cycle.
Study: 12237921
Drug: Irinotecan (CPT-11),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan (CPT-11), Paclitaxel, and Carboplatin combination therapy.
Study: 7639224
Drug: 3 U
Normalized name: Carbon 13 urea
DrugBank: Urea C-13 (DB09510)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3 U of recombinant IFN-alpha 2b three times weekly for 24 weeks
Study: 7639224
Drug: 6 U
Normalized name: vitamin E 6 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 U of recombinant IFN-alpha 2b three times weekly for 24 weeks
Study: 2988589
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg/day
Study: 29985265
Drug: ARV drugs
Normalized name: Arv-110 (protac)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARV drugs detected in HIV-uninfected young women
Study: 29985265
Drug: ARV drugs
Normalized name: Arv-110 (protac)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARV drugs detected in seroconverters
Study: 29985265
Drug: HIV drug
Normalized name: HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV drug resistance in seroconverters with genotyping results
Study: 19825505
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with dutasteride (0.5 mg) and tamsulosin (0.4 mg)
Study: 15601811
Drug: Encapsulated sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Encapsulated sumatriptan (100 mg)
Study: 10352534
Drug: Estradiol (E2)
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol (E2) transdermal treatment 50 micrograms (TTS 50) continuously administered plus Medroxyprogesterone Acetate (MPA) 10 mg/die for twelve days a month (Group A)
Study: 10352534
Drug: Conjugated Equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated Equine Estrogens (CEE) 0.625 mg/die continuously plus MPA for twelve days a month (Group B)
Study: 10352534
Drug: Estradiol transdermal
Normalized name: Estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol transdermal 50 micrograms continuously plus MPA 2.5 mg/die continuously (Group C)
Study: 10352534
Drug: CEE 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.625 mg/die continuously plus MPA 2.5 mg/die continuously (Group D)
Study: 1780205
Drug: 1.4 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.4 ml/kg of 95% ethanol, plus diluent
Study: 30887865
Drug: Citalopram 4
Normalized name: citalopram 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram 4 mg
Study: 22779219
Drug: Topical gingival
Normalized name: Bos taurus gingiva preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical gingival patch
Study: 17656440
Drug: Caffeine capsules
Normalized name: Butalbital, Aspirin, and Caffeine Capsules
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine capsules (dose = 5 mg kg(‐1)) and saline infusion ([ADR] = 0.62 nm)
Study: 17656440
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules and saline infusion ([ADR] = 0.29 nm)
Study: 17656440
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules and ADR infusion ([ADR] = 1.19 nm)
Study: 17656440
Drug: Caffeine capsules
Normalized name: Butalbital, Aspirin, and Caffeine Capsules
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeine capsules (dose = 5 mg kg(‐1)) and ADR infusion ([ADR] = 0.93 nm)
Study: 16275937
Drug: PCF (paclitaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCF (paclitaxel 175 mg/m2 on day 1, cisplatin 100 mg/m2 on day 2, FU 500 mg/m2 continuous infusion on days 2 through 6)
Study: 16275937
Drug: CF (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CF (cisplatin 100 mg/m2 on day 1 plus FU 1000 mg/m2 continuous infusion on days 1 through 5)
Study: 8536900
Drug: Octreotide (25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide (25, 50, or 100 micrograms diluted in normal saline solution)
Study: 27928851
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution (control)
Study: 26203643
Drug: Suprascapular nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprascapular nerve block plus physical therapy (PT)
Study: 11127934
Drug: Platelet glycoprotein
Normalized name: PLATELET GLYCOPROTEIN VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet glycoprotein IIb/IIIa inhibitors
Study: 9521334
Drug: Abciximab therapy
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Abciximab therapy
Study: 10757081
Drug: Bestatin (ubenimex)
Normalized name: Nystatin
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bestatin (ubenimex) 10, 30, 90, and 180 mg/day for 60 days after BMT
Study: 8353547
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy (group I)
Study: 20868559
Drug: LCAHFR combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCAHFR combined with FP chemotherapy
Study: 17227978
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with gemcitabine
Study: 25307976
Drug: Low-dose glucocorticoid
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose glucocorticoid treatment
Study: 15572415
Drug: Placebo injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injections and pills
Study: 14764753
Drug: T enanthate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: T enanthate, 200 mg im every 2 weeks with placebo pills daily (T-only)
Study: 14764753
Drug: T enanthate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: T enanthate, 200 mg every 2 weeks with 5 mg finasteride daily (T+F)
Study: 8989254
Drug: Transdermal E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal E2 for 30 days (subgroup A)
Study: 10146972
Drug: roxithromycin 150mg
Normalized name: roxithromycin
DrugBank: Roxithromycin (DB00778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxithromycin 150mg twice daily
Study: 10146972
Drug: cefaclor 250mg
Normalized name: CEFACLOR 250MG CAP
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cefaclor 250mg thrice daily
Study: 31696598
Drug: Liraglutide 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 1.8 mg once daily (QD)
Study: 31379311
Drug: Social Recovery
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Social Recovery Therapy (SRT)
Study: 26541060
Drug: 875 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 875 µg (35 000 IU) cholecalciferol (vitamin D3) per week
Study: 25966665
Drug: Edoxaban (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edoxaban (15 mg single oral dose)
Study: 22243943
Drug: Normal protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal protein diet (NP, 1 g protein:2 g carbohydrate)
Study: 22243943
Drug: Low protein
Normalized name: Low protein mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low protein diet (LP, 1 g protein:4 g carbohydrate)
Study: 12594876
Drug: Ventilator weaning
Normalized name: Noxzema Clean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ventilator weaning protocol (WP) + chlorhexidine 0.12% oral rinse administered twice daily
Study: 9743218
Drug: Fc gamma
Normalized name: Recombinant, soluble, non-glycosylated version of fc gamma receptor iib
DrugBank: Valziflocept (DB17728)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fc gamma receptor II (Fc gammaRII) and Fc gamma receptor III (Fc gammaRIII) expression on monocytes stained with specific monoclonal antibodies (IV.3 and 3G8)
Study: 7848929
Drug: Epidural analgesia
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural analgesia (EA) with 0.1% bupivacaine, 0.01% morphine sulfate
Study: 6088252
Drug: Ranitidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (300 mg)
Study: 25452446
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with docetaxel 75 mg/m2 or pemetrexed 500 mg/m2 once every 21 days
Study: 23186975
Drug: Liraglutide 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 1.8 mg once daily (OD)
Study: 14644397
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg QD
Study: 17875305
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg QD
Study: 11094868
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human IL-10 (rHuIL-10) at doses of 5, 10, or 20 micrograms/kg, administered subcutaneously, once daily for 28 days
Study: 1770154
Drug: Haloperidol 10
Normalized name: haloperidol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 10 mg daily
Study: 2871010
Drug: Haloperidol 20
Normalized name: haloperidol 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol 20 mg daily
Study: 1554036
Drug: Plasma haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Plasma haloperidol levels above 12 ng/ml
Study: 30072213
Drug: BKV or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: BKV or CMV viral loads over 10,000 copies·mL‐1
Study: 22298867
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 1500 mL of an isotonic solution per day for 6 days
Study: 22298867
Drug: Home oral
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home oral hydration therapy of 1500 mL/d (subgroup A1)
Study: 22298867
Drug: Home oral
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home oral hydration therapy of 2500 mL/d (subgroup A2)
Study: 23815562
Drug: Olmesartan (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olmesartan (20 mg)
Study: 10806134
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg)
Study: 10546920
Drug: Irbesartan (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (150 mg)
Study: 19088467
Drug: Subcutaneous epoetin
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous epoetin
Study: 19088467
Drug: Intravenous epoetin
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous epoetin
Study: 7639807
Drug: High-dose omega
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose omega 3 fatty acids (130 mg/kg/day)
Study: 2619780
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation (twice-daily dosage)
Study: 15925816
Drug: Gefitinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib (250 mg orally once a day) and Anastrozole (1 mg orally once a day)
Study: 19944363
Drug: Moderate sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate sodium restriction (120mmol to 2.8g/day) plus oral furosemide (125 to 250mg bid)
Study: 19944363
Drug: Low-sodium diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-sodium diet (80mmol to 1.8g/day) plus oral furosemide (125 to 250mg bid)
Study: 11432485
Drug: Meropenem (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem (50 mg/kg/dose, maximum 1 g, every 8 hours)
Study: 11432485
Drug: Piperacillin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin (200 mg/kg/dose, every 6 hours) plus Amikacin (15 mg/kg daily)
Study: 9712234
Drug: IgG serology
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgG serology (Orion Diagnostica Pyloriset New EIA‐G)
Study: 9712234
Drug: Capsule 14C
Normalized name: urea [14C]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule 14C urea breath test (UBT)
Study: 9712234
Drug: Non-capsule UBT
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-capsule UBT
Study: 9712234
Drug: Capsule UBT
Normalized name: MERETEK UBT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule UBT
Study: 8308505
Drug: Fluticasone aqueous
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone aqueous nasal spray 200 micrograms once daily
Study: 2658700
Drug: Inhaled propranolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled propranolol
Study: 28364870
Drug: Oral conjugated
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral conjugated equine estrogen (o-CEE, 0.45mg/day)
Study: 28364870
Drug: Transdermal 17β
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17β estradiol (t-E2, 50μg/day)
Study: 28364870
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (o-CEE, t-E2)
Study: 17205825
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 mg once per day after breakfast for 8 weeks
Study: 17205825
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Xiaoyao Decoction (XD) and Wendan Decoction (WD) one dose a day before supper for 8 weeks
Study: 1718366
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg Cu/d
Study: 31329216
Drug: AZD0530 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD0530 (100 mg or 125 mg daily)
Study: 15063421
Drug: Sildenafil (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (25 to 100 mg thrice daily)
Study: 9070958
Drug: Aspirin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (50 mg) plus dipyridamole (150 mg/day)
Study: 9070958
Drug: Aspirin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (50 mg) plus ticlopidine (200 mg/day)